Lapatinib May Target Breast Cancer Stem CellsIn a small trial of locally advanced breast cancer, lapatinib monotherapy for 6 weeks resulted in significant tumor regression, suggesting that it targets cancer stem cells.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European Cancer Organisation. These materials and the related activity are not sanctioned by the European Cancer Organisation or the commercial supporter of the conference and do not constitute an official part of that conference.
